VictoryShares US Discovery Enhanced Volatility Wtd ETF CSF 深 沪
已收盘 04-23 16:00:00 美东时间
51.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 51.03
- 总市值 2551.50万
- 52周最高 60.2845
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 48.0355
- 委 比 0.00%
- 总股本 50.00万
- 历史最高 63.1812
- 量 比 0
- 振 幅 0.00%
- 历史最低 23.3868
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initi...
08-30 05:00
武曙红：林业碳汇可堪重任，需要不断优化方法学和标准增强公信力
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
08-27 11:14
Labcorp launches FDA-cleared blood test for Alzheimer's disease
Labcorp (NYSE:LH) announced on Monday the availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, a blood-based in-vitro diagnostic test cleared by the U.S. Food and Drug Administration to aid i...
08-18 19:52
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and compr...
08-18 19:00
Matex International Faces Requisition Notice Amid Trading Suspension
An update from Matex International Limited ( ($SG:M15) ) is now available. Mate...
08-15 19:46
Plus Therapeutics Announces Data From Retrospective Analysis Of CNSide Cerebrospinal Fluid Assay Platform At SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutationsCNSide® may catalyze LM treatment initiation, allow physicians to adapt
08-14 19:37
Exicure Completes Phase 2 Trial Of GPC-100 for Stem Cell Mobilization In Multiple Myeloma; Topline Results Expected Q4 2025
Topline results expected H2 2025Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its
08-02 04:03
Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of tau in dise...
07-24 20:00
NKGen Announces It Has Received FDA Expanded Access Protocol Authorization For Treatment Of Several Neurodegenerative Diseases
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer's
07-21 20:11
